DBV Technologies S.A. (DBVT) vs Wave Life Sciences (WVE)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 18, 2026.
Summary
DBV Technologies S.A. (DBVT) has outperformed Wave Life Sciences (WVE) over the past year, losing 46.6% versus a loss of 59.9%. Over five years, DBVT leads with a -18.0% price change compared with -27.9% for WVE. Wave Life Sciences is the larger company by market cap ($616.8 million vs $568.8 million), about 1.1 times the size, while DBV Technologies S.A. is growing revenue faster (+35.8% vs -60.5%).
Wave Life Sciences converts more of its revenue into profit, with a net margin of -478.3% versus -2607.3%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | DBVT | WVE |
|---|---|---|
| Share price | $9.05 | $3.13 |
| Market cap | $568.78M | $616.76M |
| 1-day change | -0.66% | -1.88% |
| YTD return | -52.79% | -81.59% |
| 1-year return | -46.61% | -59.92% |
| 5-year return | -18.03% | -27.88% |
| EPS (TTM) | $-3.50 | $-1.08 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $5.64M | $42.73M |
| Revenue growth (YoY) | +35.77% | -60.55% |
| Net income (latest FY) | $-146.95M | $-204.38M |
| Operating margin | -2609.23% | -504.09% |
| Net margin | -2607.29% | -478.33% |
| 52-week high | $26.19 | $21.73 |
| 52-week low | $8.63 | $3.04 |
| Distance from 52-week high | -65.44% | -85.60% |
| Analyst consensus | none | strong_buy |
| Avg. price target upside | +328.07% | +450.16% |
| Average volume | 350.73K | 3.17M |
| Shares outstanding | 62.85M | 197.05M |
| Employees | 170 | 317 |
| Sector | Healthcare | Healthcare |
| Industry | Biotechnology | Biotechnology |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- DBVT has outperformed WVE by 13.3 percentage points over the past year.
- Wave Life Sciences is more profitable, keeping -478.3 cents of every revenue dollar as net income versus -2607.3 cents for DBV Technologies S.A..
- DBV Technologies S.A. grew revenue faster in its latest fiscal year (+35.77% vs -60.55%).
About DBV Technologies S.A.
DBVT stock →DBV Technologies S.A., a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products in France. Its product pipeline comprising Viaskin Peanut, an immunotherapy product, which has completed Phase 3 clinical trial for the treatment of peanut allergies; and Viaskin Milk which is in Phase 1/2 clinical trial for the treatment of immunoglobulin E (IgE) mediated or cow's milk protein allergy and eosinophilic esophagitis.
Healthcare · Biotechnology · 170 employees
About Wave Life Sciences
WVE stock →Wave Life Sciences, Inc., a clinical-stage biotechnology company, focuses on unlocking the potential of ribonucleic acid (RNA) medicines to transform human health. Its RNA medicines platform, PRISM, combines RNA medicine modalities, chemistry innovation, and deep insights in human genetics to deliver scientific breakthroughs that treat rare and common disorders.
Healthcare · Biotechnology · 317 employees
DBVT vs WVE FAQ
Which is bigger, DBV Technologies S.A. or Wave Life Sciences?
Wave Life Sciences (WVE) is larger, with a market capitalization of $616.76M compared with $568.78M for DBV Technologies S.A. (DBVT).
Which stock has performed better over the past year, DBVT or WVE?
DBVT returned -46.61% over the past 12 months, compared with -59.92% for WVE (price return, excluding dividends). Past performance does not predict future results.
Are DBV Technologies S.A. and Wave Life Sciences in the same industry?
Yes. Both are classified in the Biotechnology industry within the Healthcare sector.